An increase in international travel has seen Immuron Ltd (NASDAQ:IMRN, ASX:IMC) notch up record sales (unaudited net sales) of Travelan® this year.
Travelan® is an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract and reduces the likelihood of contracting travellers’ diarrhoea.
Immuron chief commercial officer Flavio Palumbo said: “We are excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen strong sales results in Australia over the summer peak travel period.
"We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring/summer vacation peak period.”
Record Australian sales
Sales of Travelan® in Australia in the 2024 financial year to date (YTD) as of January 2024 increased to A$2.1 million, up from A$300,000 YTD January 2023.
This comes amid a return of short-term residents to Australia, which were 31% higher in November 2023 than in November 2022, according to the Australian Bureau of Statistics.
In the USA, sales of Travelan® increased to A$600,000 in FY24 through January 2024, compared to A$300,000 YTD January 2023.
The International Trade Administration reports that total US citizen international visitor departures from the United States were 11% higher in November 2023 than in November 2022.
Meanwhile, in Canada, Immuron has recommenced sales of Travelan® through McKesson (NYSE:MCK).